Global Optimism for Research Varies Widely: Nigeria at 94%, Japan Below 50%
A global survey reveals significant variations in public optimism towards research and technology, with Nigeria showing 94% optimism while Japan shows less than 50%, highlighting the influence of socioeconomic factors and public trust on acceptance of technological advancements.
Global Optimism for Research Varies Widely: Nigeria at 94%, Japan Below 50%
A global survey reveals significant variations in public optimism towards research and technology, with Nigeria showing 94% optimism while Japan shows less than 50%, highlighting the influence of socioeconomic factors and public trust on acceptance of technological advancements.
Progress
32% Bias Score
AI Reveals Alternative Evolutionary Pathways by Creating Novel Protein
An AI system generated a new green fluorescent protein (esmGFP) that is only 58% similar to known versions, suggesting that evolution could have followed different paths and that humans might not be the only possible outcome.
AI Reveals Alternative Evolutionary Pathways by Creating Novel Protein
An AI system generated a new green fluorescent protein (esmGFP) that is only 58% similar to known versions, suggesting that evolution could have followed different paths and that humans might not be the only possible outcome.
Progress
44% Bias Score
2025: Renewed Moon Race, Space Breakthroughs, and Scientific Discoveries
In 2025, several lunar missions are underway, including a second attempt by Intuitive Machines, Firefly Aerospace's first lunar lander, and Ispace's improved spacecraft; SpaceX's Starship partially succeeded, and India achieved uncrewed space docking; scientific discoveries include a polygamous pygm...
2025: Renewed Moon Race, Space Breakthroughs, and Scientific Discoveries
In 2025, several lunar missions are underway, including a second attempt by Intuitive Machines, Firefly Aerospace's first lunar lander, and Ispace's improved spacecraft; SpaceX's Starship partially succeeded, and India achieved uncrewed space docking; scientific discoveries include a polygamous pygm...
Progress
28% Bias Score
AI Boosts Cellular Reprogramming Efficiency 50-Fold
OpenAI and Retro Biosciences developed GPT-4b, an AI model boosting the efficiency of Yamanaka proteins, key to cellular reprogramming, by 50 times in early tests, paving the way for new disease treatments.
AI Boosts Cellular Reprogramming Efficiency 50-Fold
OpenAI and Retro Biosciences developed GPT-4b, an AI model boosting the efficiency of Yamanaka proteins, key to cellular reprogramming, by 50 times in early tests, paving the way for new disease treatments.
Progress
36% Bias Score
AI Dominates \$100 Billion in Global Investments
At the 2025 Asian Financial Forum in Hong Kong, panelists highlighted AI's dominance in global investments, exceeding \$100 billion, with Saudi Arabia and Indonesia spearheading national AI strategies to boost their respective economies.
AI Dominates \$100 Billion in Global Investments
At the 2025 Asian Financial Forum in Hong Kong, panelists highlighted AI's dominance in global investments, exceeding \$100 billion, with Saudi Arabia and Indonesia spearheading national AI strategies to boost their respective economies.
Progress
36% Bias Score
Generative AI Revolutionizes Protein Design: Implications for Medicine and Future Pandemics
Geoff von Maltzahn of Flagship Pioneering discusses using generative AI to design proteins with precise functions, such as antibodies targeting viruses and creating new enzymes, highlighting the vast potential for biological discovery and its implications for human health and future pandemics.
Generative AI Revolutionizes Protein Design: Implications for Medicine and Future Pandemics
Geoff von Maltzahn of Flagship Pioneering discusses using generative AI to design proteins with precise functions, such as antibodies targeting viruses and creating new enzymes, highlighting the vast potential for biological discovery and its implications for human health and future pandemics.
Progress
48% Bias Score
AI Model GPT-4b Boosts Stem Cell Reprogramming Efficiency 50-fold
OpenAI and Retro Biosciences' AI model, GPT-4b, shows 50 times increased efficiency in applying Yamanaka factors for stem cell reprogramming, potentially revolutionizing regenerative medicine and extending human lifespan, though ethical considerations and peer review are necessary.
AI Model GPT-4b Boosts Stem Cell Reprogramming Efficiency 50-fold
OpenAI and Retro Biosciences' AI model, GPT-4b, shows 50 times increased efficiency in applying Yamanaka factors for stem cell reprogramming, potentially revolutionizing regenerative medicine and extending human lifespan, though ethical considerations and peer review are necessary.
Progress
44% Bias Score
2025: Renewed Moon Race, Starship Failure, and Scientific Breakthroughs
Multiple lunar missions launched in 2025, including Firefly Aerospace's Blue Ghost and Ispace's Resilience, aim for the moon while SpaceX's Starship test flight exploded. New discoveries in marine biology and medical history highlight scientific progress.
2025: Renewed Moon Race, Starship Failure, and Scientific Breakthroughs
Multiple lunar missions launched in 2025, including Firefly Aerospace's Blue Ghost and Ispace's Resilience, aim for the moon while SpaceX's Starship test flight exploded. New discoveries in marine biology and medical history highlight scientific progress.
Progress
24% Bias Score
2025: A New Era of Private Lunar Missions
Multiple private companies are launching lunar missions in 2025, including Intuitive Machines' second attempt, Firefly Aerospace's Blue Ghost mission to collect soil samples, and Ispace's Resilience mission carrying a rover and artwork, marking a new phase in commercial space exploration.
2025: A New Era of Private Lunar Missions
Multiple private companies are launching lunar missions in 2025, including Intuitive Machines' second attempt, Firefly Aerospace's Blue Ghost mission to collect soil samples, and Ispace's Resilience mission carrying a rover and artwork, marking a new phase in commercial space exploration.
Progress
32% Bias Score
Colossal Biosciences Secures \$200 Million in Funding, Valued at \$10.2 Billion
Colossal Biosciences, a company working to revive extinct species like the woolly mammoth, secured \$200 million in Series C funding, bringing its total funding to \$435 million and valuing the company at \$10.2 billion. The company plans to use the funds to advance genetic engineering technologies ...
Colossal Biosciences Secures \$200 Million in Funding, Valued at \$10.2 Billion
Colossal Biosciences, a company working to revive extinct species like the woolly mammoth, secured \$200 million in Series C funding, bringing its total funding to \$435 million and valuing the company at \$10.2 billion. The company plans to use the funds to advance genetic engineering technologies ...
Progress
44% Bias Score
2024 Scientific Breakthroughs: Hope and Challenges for Humanity
2024 witnessed remarkable scientific progress in diverse fields, including AI, renewable energy, genetic engineering, and medicine, offering solutions to global issues like disease, hunger, and climate change, but also raising ethical concerns.
2024 Scientific Breakthroughs: Hope and Challenges for Humanity
2024 witnessed remarkable scientific progress in diverse fields, including AI, renewable energy, genetic engineering, and medicine, offering solutions to global issues like disease, hunger, and climate change, but also raising ethical concerns.
Progress
48% Bias Score
Biotech's Binary Week: Mesoblast Soars, Percheron Crashes
In the final week of 2023, contrasting fortunes played out in the Australian biotech sector as Mesoblast shares soared 50% following US FDA approval, while Percheron shares crashed over 90% after a failed drug trial, highlighting the high-risk, high-reward nature of the industry.
Biotech's Binary Week: Mesoblast Soars, Percheron Crashes
In the final week of 2023, contrasting fortunes played out in the Australian biotech sector as Mesoblast shares soared 50% following US FDA approval, while Percheron shares crashed over 90% after a failed drug trial, highlighting the high-risk, high-reward nature of the industry.
Progress
60% Bias Score